KYTX KYVERNA THERAPEUTICS
Permanent stock page ↗Health Care · Russell 2000
Next earnings: Wed 11 Nov 2026 · estimated
What 10 analyst firms say about KYVERNA THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 10 analyst/firm records · 10 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 6 reports on KYTX from 5 analyst firms in the last 90 days (10 firms in the past year).
Comparing each firm's latest target with its previous one: 1 left it unchanged and 1 has its first observed target in the past year.
No firm's latest available rating differs from its previous one.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Benchmark | Unnamed analyst | Buy | 25 Sep 2026 | — |
| H.C. Wainwright | Mitchell S. Kapoor | Buy | 22 Oct 2026 | 25.00 USD · 25 Sep 2026 |
| JPMorgan | Brian Cheng | Buy | 13 May 2026 | 29.00 USD |
| Leerink Partners | Thomas J Smith | Buy | 26 Mar 2026 | 32.00 USD |
| Morgan Stanley | Michael Ulz | — | 15 Dec 2025 | 33.00 USD |
| Needham | Unnamed analyst | — | 25 Sep 2026 | 25.00 USD |
| Weiss Ratings | Unnamed analyst | — | 21 Sep 2026 | — |
| Wells Fargo | Derek C Archila | Buy | 13 May 2026 | 33.00 USD |
| William Blair | Matt Phipps | Buy | 23 Sep 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:56 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.